Global Pulmonary Drug Delivery Systems Market will reach 3570 million US$ by the end of 2025

This report studies the global Pulmonary Drug Delivery Systems market status and forecast, categorizes the global Pulmonary Drug Delivery Systems market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.

Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/47475/global-pulmonary-drug-delivery-systems-sales-market

With better performance, the development of DPIs is faster than the MDIs. In the future, DPIs will occupy larger market share and replace the MDIs gradually. In addition, the market share of nebulizers will be smaller.

As WHO said, the COPD will become the world’s third-leading cause of death by 2030. With the air pollution more and more serious, patients with respiratory diseases will be more and more, which means larger and larger demand for pulmonary drug delivery systems.

The global Pulmonary Drug Delivery Systems market is valued at 2560 million US$ in 2017 and will reach 3570 million US$ by the end of 2025, growing at a CAGR of 4.2% during 2018-2025.

You can also Request for a Discount- https://www.qyresearch.com/request-discount/form/47475/global-pulmonary-drug-delivery-systems-sales-market

The major players covered in this report

  • 3M
  • GSK
  • AstraZeneca
  • Cipla
  • Chiesi
  • Boehringer Ingelheim
  • Aptar
  • Novartis
  • Philips Respironics
  • Omron Healthcare
  • PARI
  • Skyepharma
  • CareFusion
  • Shanghai Huarui
  • Taian Character
  • Chia Tai Tianqing

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.

Contact US

QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA – 91748
USA: +1 626 295 2442
Email – enquiry@qyrsearch.com
Web – www.qyresearch.com

For other region, contact number given below

  • +86 108 294 5717 Beijing
  • +86 208 665 5165 Guangzhou
  • +86 215 160 1757 Shanghai
  • +852 3062 8839 HK
  • +1 613 366 5094 Canada
  • +81 903 800 9273 Japan
  • +49 176 813 78371Germany
  • +44 203 734 8135 UK
  • +33 172 813 308 France
  • +55 613 181 0478 Brazil
  • +91 114 046 9822 India